RESUMEN
Duchenne muscular dystrophy (DMD) is a lethal genetic disorder caused by an absence of the dystrophin protein in bodywide muscles, including the heart. Cardiomyopathy is a leading cause of death in DMD. Exon skipping via synthetic phosphorodiamidate morpholino oligomers (PMOs) represents one of the most promising therapeutic options, yet PMOs have shown very little efficacy in cardiac muscle. To increase therapeutic potency in cardiac muscle, we tested a next-generation morpholino: arginine-rich, cell-penetrating peptide-conjugated PMOs (PPMOs) in the canine X-linked muscular dystrophy in Japan (CXMDJ) dog model of DMD. A PPMO cocktail designed to skip dystrophin exons 6 and 8 was injected intramuscularly, intracoronarily, or intravenously into CXMDJ dogs. Intravenous injections with PPMOs restored dystrophin expression in the myocardium and cardiac Purkinje fibers, as well as skeletal muscles. Vacuole degeneration of cardiac Purkinje fibers, as seen in DMD patients, was ameliorated in PPMO-treated dogs. Although symptoms and functions in skeletal muscle were not ameliorated by i.v. treatment, electrocardiogram abnormalities (increased Q-amplitude and Q/R ratio) were improved in CXMDJ dogs after intracoronary or i.v. administration. No obvious evidence of toxicity was found in blood tests throughout the monitoring period of one or four systemic treatments with the PPMO cocktail (12 mg/kg/injection). The present study reports the rescue of dystrophin expression and recovery of the conduction system in the heart of dystrophic dogs by PPMO-mediated multiexon skipping. We demonstrate that rescued dystrophin expression in the Purkinje fibers leads to the improvement/prevention of cardiac conduction abnormalities in the dystrophic heart.
Asunto(s)
Cardiomiopatías/terapia , Péptidos de Penetración Celular/farmacología , Distrofina/metabolismo , Exones , Morfolinos/farmacología , Distrofia Muscular Animal/terapia , Distrofia Muscular de Duchenne/terapia , Animales , Cardiomiopatías/etiología , Modelos Animales de Enfermedad , Perros , Femenino , Terapia Genética , Masculino , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Distrofia Muscular Animal/complicaciones , Distrofia Muscular Animal/genética , Distrofia Muscular de Duchenne/complicaciones , Distrofia Muscular de Duchenne/genéticaRESUMEN
It is expected that serum protein biomarkers in Duchenne muscular dystrophy (DMD) will reflect disease pathogenesis, progression and aid future therapy developments. Here, we describe use of quantitative in vivo stable isotope labeling in mammals to accurately compare serum proteomes of wild-type and dystrophin-deficient mdx mice. Biomarkers identified in serum from two independent dystrophin-deficient mouse models (mdx-Δ52 and mdx-23) were concordant with those identified in sera samples of DMD patients. Of the 355 mouse sera proteins, 23 were significantly elevated and 4 significantly lower in mdx relative to wild-type mice (P-value < 0.001). Elevated proteins were mostly of muscle origin: including myofibrillar proteins (titin, myosin light chain 1/3, myomesin 3 and filamin-C), glycolytic enzymes (aldolase, phosphoglycerate mutase 2, beta enolase and glycogen phosphorylase), transport proteins (fatty acid-binding protein, myoglobin and somatic cytochrome-C) and others (creatine kinase M, malate dehydrogenase cytosolic, fibrinogen and parvalbumin). Decreased proteins, mostly of extracellular origin, included adiponectin, lumican, plasminogen and leukemia inhibitory factor receptor. Analysis of sera from 1 week to 7 months old mdx mice revealed age-dependent changes in the level of these biomarkers with most biomarkers acutely elevated at 3 weeks of age. Serum analysis of DMD patients, with ages ranging from 4 to 15 years old, confirmed elevation of 20 of the murine biomarkers in DMD, with similar age-related changes. This study provides a panel of biomarkers that reflect muscle activity and pathogenesis and should prove valuable tool to complement natural history studies and to monitor treatment efficacy in future clinical trials.
Asunto(s)
Envejecimiento/sangre , Proteínas Sanguíneas/metabolismo , Distrofina/deficiencia , Distrofia Muscular Animal/sangre , Distrofia Muscular de Duchenne/sangre , Adolescente , Envejecimiento/genética , Envejecimiento/patología , Animales , Biomarcadores/sangre , Proteínas Sanguíneas/genética , Niño , Preescolar , Análisis por Conglomerados , Distrofina/genética , Femenino , Expresión Génica , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos mdx , Anotación de Secuencia Molecular , Distrofia Muscular Animal/genética , Distrofia Muscular Animal/patología , Distrofia Muscular de Duchenne/genética , Distrofia Muscular de Duchenne/patología , Especificidad de la EspecieAsunto(s)
Regulación del Desarrollo de la Expresión Génica , Músculo Esquelético/citología , Células Satélite del Músculo Esquelético/metabolismo , Animales , Ratones , Factor de Transcripción PAX3 , Factor de Transcripción PAX7/metabolismo , Factores de Transcripción Paired Box/metabolismo , Regeneración , Células Satélite del Músculo Esquelético/fisiología , Factores de TiempoRESUMEN
A new line of dystrophic mdx mice on the DBA/2J (D2) background has emerged as a candidate to study the efficacy of therapeutic approaches for Duchenne muscular dystrophy (DMD). These mice harbor genetic polymorphisms that appear to increase the severity of the dystropathology, with disease modifiers that also occur in DMD patients, making them attractive for efficacy studies and drug development. This workshop aimed at collecting and consolidating available data on the pathological features and the natural history of these new D2/mdx mice, for comparison with classic mdx mice and controls, and to identify gaps in information and their potential value. The overall aim is to establish guidance on how to best use the D2/mdx mouse model in preclinical studies.
Asunto(s)
Modelos Animales de Enfermedad , Distrofia Muscular Animal , Distrofia Muscular de Duchenne , Animales , Ratones , Ratones Endogámicos DBA , Ratones Endogámicos mdxAsunto(s)
Comunicación Celular/fisiología , Células Musculares/fisiología , Músculo Esquelético/citología , Células Madre/citología , Angiopoyetina 1/fisiología , Animales , División Celular , Linaje de la Célula , Células Cultivadas/citología , Fibroblastos/citología , Humanos , Ratones , Modelos Biológicos , Músculo Liso/citología , Receptor TIE-2/fisiología , Transducción de Señal/fisiologíaAsunto(s)
Células de la Médula Ósea/citología , Diferenciación Celular , Células Musculares/citología , Enfermedades Musculares/terapia , Trasplante de Células Madre , Animales , Humanos , Ratones , Músculo Esquelético/citología , Distrofia Muscular de Duchenne/terapia , Receptores Notch/genética , Células del Estroma/citología , TransfecciónRESUMEN
Myoblast transplantation was the first quasi-gene therapy to be suggested for Duchenne muscular dystrophy. Animal experiments established the principles that the missing gene could be targeted to muscle by grafting of genetically normal myoblasts that were able to repair the disease-damaged muscle fibres. In the recipient muscle the gene was expressed and the resultant protein provided some functional benefit in protecting the fibres against necrosis. However, these effects were limited to a small region around the injection site and there was some evidence of immunological problems. Human trials provided little evidence of effectiveness probably, in part due to immune rejection, and in part to the inadequacy of the cells implanted. Most work since this time has been directed at preventing immune rejection, improving dispersion of the injected cells, and selecting more 'stem cell-like' myogenic cells which might be more effective at reconstituting large regions of muscle. Most recently, a number of sources of 'stem cell' with myogenic potential have been described, some of which have been found to be dispersed via the blood vascular system but none of which have been very efficient at generating new muscle.
Asunto(s)
Trasplante de Células/tendencias , Enfermedades Musculares/cirugía , Mioblastos Esqueléticos/trasplante , Animales , Trasplante de Células/efectos adversos , Técnicas de Transferencia de Gen/tendencias , Terapia Genética/tendencias , Humanos , Fibras Musculares Esqueléticas/patología , Enfermedades Musculares/patología , Distrofia Muscular de Duchenne/cirugíaRESUMEN
Constraint of stem cell number in skeletal muscle is investigated by Abou-Khalil et al. (2009), in this issue of Cell Stem Cell. Their results attribute it both to autocrine positive feedback and to paracrine signals from the surrounding cellular community.
Asunto(s)
Células Satélite del Músculo Esquelético/citología , Células Satélite del Músculo Esquelético/metabolismo , Células Madre/citología , Angiopoyetina 1/metabolismo , Angiopoyetina 1/farmacología , Animales , Comunicación Autocrina/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Humanos , Ratones , Comunicación Paracrina/efectos de los fármacos , Receptor TIE-2/metabolismo , Células Satélite del Músculo Esquelético/efectos de los fármacos , Células Satélite del Músculo Esquelético/enzimología , Células Madre/efectos de los fármacos , Células Madre/metabolismoRESUMEN
Satellite cells are dormant progenitors located at the periphery of skeletal myofibers that can be triggered to proliferate for both self-renewal and differentiation into myogenic cells. In addition to anatomic location, satellite cells are typified by markers such as M-cadherin, Pax7, Myf5, and neural cell adhesion molecule-1. The Pax3 and Pax7 transcription factors play essential roles in the early specification, migration, and myogenic differentiation of satellite cells. In addition to muscle-committed satellite cells, multi-lineage stem cells encountered in embryonic, as well as adult, tissues exhibit myogenic potential in experimental conditions. These multi-lineage stem cells include side-population cells, muscle-derived stem cells (MDSCs), and mesoangioblasts. Although the ontogenic derivation, identity, and localization of these non-conventional myogenic cells remain elusive, recent results suggest their ultimate origin in blood vessel walls. Indeed, purified pericytes and endothelium-related cells demonstrate high myogenic potential in culture and in vivo. Allogeneic myoblasts transplanted into Duchenne muscular dystrophy (DMD) patients have been, in early trials, largely inefficient owing to immune rejection, rapid death, and limited intramuscular migration--all obstacles that are now being alleviated, at least in part, by more efficient immunosuppression and escalated cell doses. As an alternative to myoblast transplantation, stem cells such as mesoangioblasts and CD133+ progenitors administered through blood circulation have recently shown great potential to regenerate dystrophic muscle.
Asunto(s)
Músculo Esquelético/crecimiento & desarrollo , Distrofia Muscular de Duchenne/terapia , Trasplante de Células Madre/métodos , Células Madre/citología , Animales , Diferenciación Celular , Humanos , Modelos Biológicos , Músculo Esquelético/citología , Músculo Esquelético/metabolismo , Distrofia Muscular de Duchenne/patología , Factor de Transcripción PAX7/metabolismo , Células Satélite del Músculo Esquelético/citología , Células Satélite del Músculo Esquelético/metabolismo , Células Madre/metabolismoRESUMEN
Low energy laser irradiation (LELI) has been shown to promote skeletal muscle cell activation and proliferation in primary cultures of satellite cells as well as in myogenic cell lines. Here, we have extended these studies to isolated myofibers. These constitute the minimum viable functional unit of the skeletal muscle, thus providing a close model of in vivo regeneration of muscle tissue. We show that LELI stimulates cell cycle entry and the accumulation of satellite cells around isolated single fibers grown under serum-free conditions and that these effects act synergistically with the addition of serum. Moreover, for the first time we show that LELI promotes the survival of fibers and their adjacent cells, as well as cultured myogenic cells, under serum-free conditions that normally lead to apoptosis. In both systems, expression of the anti-apoptotic protein Bcl-2 was markedly increased, whereas expression of the pro-apoptotic protein BAX was reduced. In culture, these changes were accompanied by a reduction in the expression of p53 and the cyclin-dependent kinase inhibitor p21, reflecting the small decrease in viable cells 24 hours after irradiation. These findings implicate regulation of these factors as part of the protective role of LELI against apoptosis. Taken together, our findings are of critical importance in attempts to improve muscle regeneration following injury.